<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760368</url>
  </required_header>
  <id_info>
    <org_study_id>CL04041022</org_study_id>
    <secondary_id>2014-004719-36</secondary_id>
    <nct_id>NCT02760368</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease</brief_title>
  <acronym>CREDO 1</acronym>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Pharm International, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OCT Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mene Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>R-Pharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine how effective and safe the study drug Olokizumab&#xD;
      is, in patients with Rheumatoid Arthritis (RA) who are already receiving, but not fully&#xD;
      responding to, treatment with methotrexate (MTX).&#xD;
&#xD;
      The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg&#xD;
      administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w)&#xD;
      relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA)&#xD;
      inadequately controlled by methotrexate (MTX) therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this Phase III study was to assess the efficacy, tolerability, and safety of OKZ&#xD;
      in subjects with moderately to severely active RA who have responded inadequately to MTX. The&#xD;
      primary endpoint of the trial was at Week 12. Olokizumab was expected to reduce the disease&#xD;
      activity and improve physical function. The study was expected to provide safety information&#xD;
      in a large group of subjects over at least a 24 week period.&#xD;
&#xD;
      The CREDO 1 study included a 4-week Screening Period, a double-blind Treatment Period from&#xD;
      Week 0 to Week 24, and a Safety Follow-Up Period from Week 24 to Week 44.&#xD;
&#xD;
      At randomization, a total of 420 eligible subjects were randomly assigned to 1 of 3 treatment&#xD;
      groups in a 1:1:1 ratio:&#xD;
&#xD;
        1. OKZ 64 mg q4w: SC injection of OKZ 64 mg q4w (alternating with SC injection of placebo&#xD;
           OKZ q4w to maintain blinding) + MTX.&#xD;
&#xD;
        2. OKZ 64 mg q2w: SC injection of OKZ 64 mg q2w + MTX.&#xD;
&#xD;
        3. Placebo: SC injection of placebo q2w + MTX&#xD;
&#xD;
      Throughout the double-blind Treatment Period, all subjects were required to remain on a&#xD;
      stable dose of background MTX at 15 to 25 mg/week (or ≥ 10 mg/week if there was documented&#xD;
      intolerance to higher doses) with a stable route of administration, and concomitant treatment&#xD;
      with folic acid ≥5 mg per week or equivalent is required for all subjects. The last dose of&#xD;
      study treatment (OKZ or placebo) was at Week 22 in all groups.&#xD;
&#xD;
      Following Visit 2 (randomization), subjects returned to the study site at least every other&#xD;
      week through Week 24 for response and safety assessments as per the study Schedule of Events.&#xD;
&#xD;
      Subjects were classified in terms of their response to study treatment at Week 14, with&#xD;
      nonresponders defined as subjects in any treatment group who do not improve by at least 20%&#xD;
      in both swollen and tender joint counts (66-68 joint assessment). Starting at or as close as&#xD;
      possible to Week 14, non-responders were administered sulfasalazine and/or hydroxychloroquine&#xD;
      as rescue medication in addition to the assigned treatment.&#xD;
&#xD;
      After completion of the 24-week double-blind Treatment Period, subjects either rolled over&#xD;
      into the long-term open-label extension (OLE) study or entered the Safety Follow-Up Period.&#xD;
      During the Safety Follow-Up Period, subjects returned for visits +4, +8, and +22 weeks after&#xD;
      the last dose of study treatment.&#xD;
&#xD;
      Subjects who discontinued the randomized treatment prematurely were required to come for the&#xD;
      End of Treatment (EoT) Visit 2 weeks after the last study treatment administration and then&#xD;
      continued with the scheduled study visits as per the Schedule of Events.&#xD;
&#xD;
      The study was conducted at approximately 50 sites across 4 countries globally, which included&#xD;
      Russia, Belarus, Turkey, and Bulgaria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR20 Response</measure>
    <time_frame>at Week 12</time_frame>
    <description>The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. (a responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference Between OKZ and Placebo in the Percentage of Subjects Achieving Low Disease Activity</measure>
    <time_frame>at Week 12</time_frame>
    <description>Defined as DAS28 (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between OKZ and Placebo in the Improvement of Physical Ability</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>As measured by the Health Assessment Questionnaire Disability Index (HAQ DI) HAQ-DI provides an assessment of the impact of the disease and its treatment on physical function. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR50 Response</measure>
    <time_frame>at Week 24</time_frame>
    <description>Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤2.8 (Remission)</measure>
    <time_frame>at Week 24</time_frame>
    <description>Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 24</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">428</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Olokizumab q4w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olokizumab 64 mg Subcutaneous q4w +placebo+ Methotrexate (oral) in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Olokizumab q2w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Subcutaneous q2w + Methotrexate (oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olokizumab</intervention_name>
    <description>160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial</description>
    <arm_group_label>Arm 1: Olokizumab q4w</arm_group_label>
    <arm_group_label>Arm 2: Olokizumab q2w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules</description>
    <arm_group_label>Arm 1: Olokizumab q4w</arm_group_label>
    <arm_group_label>Arm 3: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects may be enrolled in the study only if they meet all of the following criteria:&#xD;
&#xD;
          -  Subjects willing and able to sign informed consent&#xD;
&#xD;
          -  Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised&#xD;
             classification criteria for RA for at least 12 weeks prior to Screening.&#xD;
&#xD;
          -  Inadequate response to treatment with MTX for at least 12 weeks prior to Screening at&#xD;
             a dose of 15 to 25 mg/week (or ≥10 mg/week if intolerant to higher doses).&#xD;
&#xD;
               -  The dose and means of administering MTX must have been stable for at least 6&#xD;
                  weeks prior to Screening.&#xD;
&#xD;
          -  Subjects must be willing to take folic acid or equivalent throughout the study&#xD;
&#xD;
          -  Subjects must have moderately to severely active RA disease as defined by all of the&#xD;
             following:&#xD;
&#xD;
               -  ≥6 tender joints (68 joint count) at Screening and baseline; and&#xD;
&#xD;
               -  ≥6 swollen joints (66 joint count) at Screening and baseline; and&#xD;
&#xD;
               -  CRP above ULN at Screening based on the central laboratory results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g.,&#xD;
             gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile&#xD;
             idiopathic arthritis, or systemic lupus erythematosus). However, subjects may have&#xD;
             secondary Sjogren's syndrome or hypothyroidism&#xD;
&#xD;
          -  Subjects who are Steinbrocker class IV functional capacity (incapacitated, largely or&#xD;
             wholly bed-ridden or confined to a wheelchair, with little or no self-care)&#xD;
&#xD;
          -  Prior exposure to any licensed or investigational compound directly or indirectly&#xD;
             targeting IL 6 or IL 6R (including tofacitinib or other Janus kinases and spleen&#xD;
             tyrosine kinase [SYK] inhibitors)&#xD;
&#xD;
          -  Prior treatment with cell depleting therapies including anti CD20 or investigational&#xD;
             agents (e.g., CAMPATH, anti CD4, anti CD5, anti CD3, and anti CD19)&#xD;
&#xD;
          -  Prior use of bDMARDs, with the following exception:&#xD;
&#xD;
             • Subjects who discontinued TNFi therapy due to a reason other than lack of efficacy&#xD;
             are allowed to enter the study (TNFi therapy should not be discontinued to facilitate&#xD;
             a subject's participation in the study, but should instead have been previously&#xD;
             discontinued as part of a subject's medical management of RA). The use of TNFi therapy&#xD;
             within the following windows prior to baseline is exclusionary: i. 4 weeks for&#xD;
             etanercept ii. 8 weeks for infliximab iii. 10 weeks for adalimumab, certolizumab, and&#xD;
             golimumab&#xD;
&#xD;
          -  Use of parenteral and/or intra-articular glucocorticoids within 4 weeks prior to&#xD;
             baseline&#xD;
&#xD;
          -  Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent) or&#xD;
             change in dosage within 2 weeks prior to baseline&#xD;
&#xD;
          -  Prior documented history of no response to hydroxychloroquine and sulfasalazine&#xD;
&#xD;
          -  Prior use of cDMARDs (other than MTX) within the following windows prior to baseline&#xD;
             (cDMARDs should not be discontinued to facilitate a subject's participation in the&#xD;
             study, but should instead have been previously discontinued as part of a subject's&#xD;
             medical management of RA):&#xD;
&#xD;
               1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine,&#xD;
                  chloroquine, gold, penicillamine, minocycline, or d oxycycline&#xD;
&#xD;
               2. 12 weeks for leflunomide unless the subject has completed the following&#xD;
                  elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a&#xD;
                  dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a&#xD;
                  dosage of 50 grams 4 times daily for at least 24 hours&#xD;
&#xD;
               3. 24 weeks for cyclophosphamide&#xD;
&#xD;
          -  Vaccination with live vaccines in the 6 weeks prior to baseline or planned vaccination&#xD;
             with live vaccines during the study&#xD;
&#xD;
          -  Participation in any other investigational drug study within 30 days or 5 times the&#xD;
             terminal half-life of the investigational drug, whichever is longer, prior to baseline&#xD;
&#xD;
          -  Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to&#xD;
             baseline&#xD;
&#xD;
          -  Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline&#xD;
&#xD;
          -  Use of non-steroidal anti-inflammatory drugs (NSAIDs) on unstable dose or switching of&#xD;
             NSAIDs within 2 weeks prior to baseline&#xD;
&#xD;
          -  Previous participation in this study (randomized) or another study of OKZ&#xD;
&#xD;
          -  Abnormal laboratory values, as defined below:&#xD;
&#xD;
               1. Creatinine level ≥ 1.5 mg/dL (132 µmol/L) for females or ≥ 2.0 mg/dL (177 µmol/L)&#xD;
                  for males&#xD;
&#xD;
               2. ALT or AST level ≥ 1.5× ULN&#xD;
&#xD;
               3. Platelets &lt;100×10^9/L (&lt;100,000/mm^3)&#xD;
&#xD;
               4. White blood cell count &lt;3.5×10^9/L&#xD;
&#xD;
               5. Neutrophil count &lt;2000×10^6/L (&lt;2000/mm^3)&#xD;
&#xD;
               6. Hemoglobin level ≤ 80 g/L&#xD;
&#xD;
               7. Glycosylated hemoglobin (HbA1c) level ≥ 8%&#xD;
&#xD;
          -  Subjects with concurrent acute or chronic viral hepatitis B or C infection as detected&#xD;
             by blood tests at Screening (e.g., positive for hepatitis B surface antigen [HBsAg],&#xD;
             total hepatitis B core antibody [anti-HBc], or hepatitis C virus antibody [HCV Ab])&#xD;
&#xD;
             a) Subjects who are positive for hepatitis B surface antibody (anti-HBs), but negative&#xD;
             for HBsAg and anti-HBc, will be eligible.&#xD;
&#xD;
          -  Subjects with HIV infection&#xD;
&#xD;
          -  Subjects with current active TB infection or a history of active TB infection&#xD;
&#xD;
          -  Close contact (i.e., sharing the same household or other enclosed environment, such as&#xD;
             a social gathering place, workplace, or facility, for extended periods during the day)&#xD;
             with an individual with active TB within 1.5 years prior to Screening&#xD;
&#xD;
          -  History of untreated latent TB infection (LTBI), regardless of IGRA result at&#xD;
             Screening i. Subjects with a history of untreated LTBI may be re-screened and enrolled&#xD;
             if they fulfill all 3 of the following criteria:&#xD;
&#xD;
               1. Active TB is ruled out by a certified TB specialist or pulmonologist who is&#xD;
                  familiar with diagnosing and treating TB (as acceptable per local practice);&#xD;
&#xD;
               2. The subject has completed at least 30 days of LTBI-appropriate prophylaxis prior&#xD;
                  to baseline with agents recommended as preventative therapy for LTBI according to&#xD;
                  country-specific/Centers for Disease Control and Prevention (CDC) guidelines&#xD;
                  (treatment with isoniazid for 6 months is not an appropriate prophylactic regime&#xD;
                  for this study and it should not be used); and&#xD;
&#xD;
               3. The subject is willing to complete the entire course of recommended LTBI therapy&#xD;
&#xD;
          -  Positive interferon-gamma release assay (IGRA) result at Screening. If indeterminate,&#xD;
             the IGRA can be repeated once during the Screening Period. If there is a second&#xD;
             indeterminate result, the subject will be excluded.&#xD;
&#xD;
             i. Subjects with a positive IGRA result at Screening may be re-screened and enrolled&#xD;
             if they fulfill all 3 of the following criteria:&#xD;
&#xD;
               1. Active TB is ruled out by a certified TB specialist or pulmonologist who is&#xD;
                  familiar with diagnosing and treating TB (as acceptable per local practice);&#xD;
&#xD;
               2. The subject has completed at least 30 days of LTBI-appropriate prophylaxis prior&#xD;
                  to baseline with agents recommended as preventative therapy for LTBI according to&#xD;
                  country-specific/CDC guidelines (treatment with isoniazid for 6 months is not an&#xD;
                  appropriate prophylactic regime for this study and it should not be used); and&#xD;
&#xD;
               3. The subject is willing to complete the entire course of recommended LTBI therapy.&#xD;
&#xD;
                  ii.If a subject with a positive IGRA result at Screening has documented evidence&#xD;
                  of completing treatment for LTBI with a treatment regime and treatment duration&#xD;
                  that are appropriate for this study, the subject may be enrolled without further&#xD;
                  prophylaxis if recommended by a certified TB specialist or pulmonologist who is&#xD;
                  familiar with diagnosing and treating TB (as acceptable per local practice) and&#xD;
                  no new exposure in close contact with an individual with active TB after&#xD;
                  completing the prophylactic treatment is suspected&#xD;
&#xD;
          -  Concurrent malignancy or a history of malignancy within the last 5 years (with the&#xD;
             exception of successfully treated carcinoma of the cervix in situ and successfully&#xD;
             treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to&#xD;
             Screening [and no more than 3 excised skin cancers within the last 5 years prior to&#xD;
             Screening])&#xD;
&#xD;
          -  Subjects with any of the following CV conditions:&#xD;
&#xD;
               1. Uncompensated congestive heart failure, or class III or IV heart failure defined&#xD;
                  by the New York Heart Association classification (The Criteria Committee of the&#xD;
                  New York Heart Association, 1994)&#xD;
&#xD;
               2. Untreated or resistant arterial hypertension Grade II-III (systolic blood&#xD;
                  pressure [BP] &gt; 160 mm Hg and/or diastolic BP &gt;100 mm Hg)&#xD;
&#xD;
               3. History or presence of concurrent severe and/or uncontrolled CV disorder&#xD;
                  (including but not limited to acute coronary syndrome or stroke/transient&#xD;
                  ischemic attack in the previous 3 months before Screening) that would, in the&#xD;
                  Investigator's judgment, contraindicate subject participation in the clinical&#xD;
                  study, or clinically significant enough in the opinion of the Investigator to&#xD;
                  alter the disposition of the study treatment, or constitute a possible&#xD;
                  confounding factor for assessment of efficacy or safety of the study treatment&#xD;
&#xD;
          -  Subjects with a history or presence of any concurrent severe and/or uncontrolled&#xD;
             medical condition (including but not limited to respiratory, hepatic, renal, GI,&#xD;
             endocrinological, dermatological, neurological, psychiatric, hematological [including&#xD;
             bleeding disorder], or immunologic/immunodeficiency disorder[s]) that would, in the&#xD;
             Investigator's judgment, contraindicate subject participation in the clinical study,&#xD;
             or clinically significant enough in the opinion of the Investigator to alter the&#xD;
             disposition of the study treatment, or constitute a possible confounding factor for&#xD;
             assessment of efficacy or safety of the study treatment&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2&#xD;
             weeks prior to Screening or at baseline, injectable anti-infective therapy in the last&#xD;
             4 weeks prior to baseline, or serious or recurrent infection with history of&#xD;
             hospitalization in the 6 months prior to baseline&#xD;
&#xD;
          -  Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis,&#xD;
             meningitis, or other non-self-limited herpes zoster infections in the 6 months prior&#xD;
             to baseline&#xD;
&#xD;
          -  Subjects with planned surgery during the study or surgery ≤4 weeks prior to Screening&#xD;
             and from which the subject has not fully recovered, as judged by the Investigator&#xD;
&#xD;
          -  Subjects with diverticulitis or other symptomatic GI conditions that might predispose&#xD;
             the subject to perforations, including subjects with a history of such predisposing&#xD;
             conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis)&#xD;
&#xD;
          -  Pre-existing central nervous system demyelinating disorders (e.g., multiple sclerosis&#xD;
             and optic neuritis)&#xD;
&#xD;
          -  History of chronic alcohol or drug abuse as judged by the Investigator&#xD;
&#xD;
          -  Female subjects who are pregnant, currently lactating, have lactated within the last&#xD;
             12 weeks, or who are planning to become pregnant during the study or within 6 months&#xD;
             of last dose of study treatment&#xD;
&#xD;
          -  Female subjects of childbearing potential (unless permanent cessation of menstrual&#xD;
             periods, determined retrospectively after a woman has experienced 12 months of natural&#xD;
             amenorrhea as defined by the amenorrhea with underlying status [e.g., correlative age]&#xD;
             or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone&#xD;
             levels &gt;40 mIU/mL and estradiol &lt;20 pg/mL) who are not willing to use a highly&#xD;
             effective method of contraception during the study OR Male subjects with partners of&#xD;
             childbearing potential not willing to use a highly effective method of contraception&#xD;
             during the study and for at least 3 months after the last administration of study&#xD;
             treatment&#xD;
&#xD;
          -  Subjects with a known hypersensitivity to any component of the OKZ drug product, or&#xD;
             placebo&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to human, humanized, or murine&#xD;
             monoclonal antibodies&#xD;
&#xD;
          -  Subject's unwillingness or inability to follow the procedures outlined in the protocol&#xD;
&#xD;
          -  Other medical or psychiatric conditions or laboratory abnormalities that may increase&#xD;
             potential risk associated with study participation and administration of&#xD;
             investigational products, or that may affect study results interpretation and, as per&#xD;
             the Investigator's judgment, make the subject ineligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Samsonov</last_name>
    <role>Study Director</role>
    <affiliation>R-Pharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City Clinical Hospital #1</name>
      <address>
        <city>Minsk</city>
        <zip>220013</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitebsk Regional Clinical Hospital</name>
      <address>
        <city>Vitebsk</city>
        <zip>210037</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC 'Sv. Pantaleymon' OOD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Kaspela&quot;, EOOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sv. Ivan Rilski&quot;, EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC &quot;Synexus - Sofia&quot;, EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Budgetary Healthcare Institution &quot;Barnaul City Hospital #4&quot;</name>
      <address>
        <city>Barnaul</city>
        <state>Altai Region</state>
        <zip>656050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center LLC &quot;Maksimum Zdoroviya&quot;</name>
      <address>
        <city>Kemerovo</city>
        <state>Kemerovo Oblast</state>
        <zip>650056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAHI of Kemerovo region &quot;Regional Clinical Hospital for War Veterans&quot;</name>
      <address>
        <city>Kemerovo</city>
        <state>Kemerovskaya Oblast</state>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budgetary Healthcare Institution &quot;Kursk Regional Clinical Hospital&quot; of Healthcare Committee of Kursk region</name>
      <address>
        <city>Kursk</city>
        <state>Kurskaya Oblast</state>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBHI &quot;Clinical Rheumatological Hospital #25&quot;, Fourth Rheumatology Unit</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningradskaya Oblast</state>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Moscow &quot;City Clinical Hospital #1 n.a. Pirogov&quot; Healthcare Departament of Moscow</name>
      <address>
        <city>Moscow</city>
        <state>Moscovskaya Oblast</state>
        <zip>119094</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBEI HE &quot;First Moscow State Medical University n.a. I.M. Sechenov of MoH of Russian Federation&quot;, UCH #1</name>
      <address>
        <city>Moscow</city>
        <state>Moscovskaya Oblast</state>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBEI HE &quot;FMSMU n.a. I.M. Sechenov of MoH of RF&quot;, University Hospital #2, Departament of New Drugs Introduction</name>
      <address>
        <city>Moscow</city>
        <state>Moscovskaya Oblast</state>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE &quot;First Moscow State Medical University n.a. I.M. Sechenov of MoH of Russian Federation&quot; UCH #3</name>
      <address>
        <city>Moscow</city>
        <state>Moscovskaya Oblast</state>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution &quot;City Clinical Hospital # 15 n.a O.M. Filatov&quot; of Moscow Healtheare Department</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Region</state>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of Moscow &quot;City Clinical Hospital #4 of Moscow Healthcare Departament&quot;</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaya Oblast</state>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of Nizhny Novgorod Region &quot;Nizhny Novgorod Regional Clinical Hospital n.a.Semashko&quot;</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <state>Nizhegorodskaya Oblast</state>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthcare Institution of Novosibirsk region &quot;City Polyclinic #1&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirsk Oblast</state>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Clinical Diagnostic Center &quot;Ultramed&quot;</name>
      <address>
        <city>Omsk</city>
        <state>Omskaya Oblast</state>
        <zip>644024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budgetary Healthcare Institution of Omsk Region &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Omsk</city>
        <state>Omskaya Oblast</state>
        <zip>644111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of the Republic of Karelia &quot;Republican Hospital named after V.A. Baranov&quot;</name>
      <address>
        <city>Petrozavodsk</city>
        <state>Republic Of Karelia</state>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution &quot;Republican Clinical Hospital n.a. G.G. Kuvatov&quot;</name>
      <address>
        <city>Ufa</city>
        <state>Respublic Of Bashkortostan</state>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE &quot;Rostov State Medical University&quot; of Ministry of Health of the Russian Federation</name>
      <address>
        <city>Rostov</city>
        <state>Rostovskaya Oblast</state>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE &quot;SSMU n.a. V.I. Razumovsky of MoH of RF&quot;, Clinical Hospital n.a. S.R. Mirotvorcev, Therapeutic Departament</name>
      <address>
        <city>Saratov</city>
        <state>Saratovskaya Oblast</state>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Saratov</city>
        <state>Saratovskaya Oblast</state>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-governmental Healtheare Institution &quot;Regional Clinical Hospital at Smolensk station of OJSC &quot;Russian Railways&quot;</name>
      <address>
        <city>Smolensk</city>
        <state>Smolenskaya Oblast</state>
        <zip>214025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of Stavropol Region &quot;Stavropol Regional Clinical Hospital&quot;</name>
      <address>
        <city>Stavropol'</city>
        <state>Stavropol Region</state>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Sverdlovsk Region &quot;Sverdlovsk Regional Clinical Hospital #1&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovskaya Oblast</state>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE &quot;Ural State Medical University&quot; of MoH of RF based MBI &quot;Central City Clinical Hospital #6&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovskaya Oblast</state>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthcare Institution &quot;Republican Clinical Hospital of Ministry of Health of Tatarstan Republic</name>
      <address>
        <city>Kazan'</city>
        <state>The Republic Of Tatarstan</state>
        <zip>420064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Tula region &quot;Tula Regional Clinical Hospital&quot;</name>
      <address>
        <city>Tula</city>
        <state>Tulskaya Oblast</state>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Ulyanovsk Regional Clinical Hospital&quot;</name>
      <address>
        <city>Ulyanovsk</city>
        <state>Ulyanovskaya Oblast</state>
        <zip>432063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of Vladimir Region &quot;Regional Clinical Hospital&quot;, Rheumatology Departament</name>
      <address>
        <city>Vladimir</city>
        <state>Vladimirskaya Oblast</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Helthcare Institution of Yaroslavl region &quot;Clinical Hospital of Emergency Care n.a. Solovyev&quot;</name>
      <address>
        <city>Yaroslavl'</city>
        <state>Yaroslavsakaya Oblast</state>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI &quot;Yaroslavl Regional Clinical Hospital&quot;, Rheumatology department</name>
      <address>
        <city>Yaroslavl'</city>
        <state>Yaroslavskaya Oblast</state>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBSI &quot;Scientific Research Institute of Rheumatology n.a. V.A. Nasonova&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Tekhnologii Zdoroviya&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191144</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI &quot;North-West Federat Medical Research Center n.a. V.A.Almazov&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>Turkey</country>
  </removed_countries>
  <link>
    <url>http://acrabstracts.org/abstract/safety-and-efficacy-of-olokizumab-in-a-phase-iii-trial-of-patients-with-moderately-to-severely-active-rheumatoid-arthritis-inadequately-controlled-by-methotrexate-credo1-study/</url>
    <description>Nasonov E, Fatenejad S, Korneva E, Krechikova D. - Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate - CREDO1 Study [abstract].</description>
  </link>
  <link>
    <url>http://scientific.sparx-ip.net/archiveeular/?c=a&amp;searchfor=olokizumab&amp;view=1&amp;item=2020OP0021</url>
    <description>E. Nasonov, R. Stoilov, T. Tyabut, M. C. Genovese. 2020 OP0021 Olokizumab, Monoclonal Antibody Against IL6, in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate:Results of Phase III CREDO-1 study</description>
  </link>
  <link>
    <url>http://scientific.sparx-ip.net/archiveeular/?c=a&amp;searchfor=olokizumab&amp;view=1&amp;item=2020THU0176</url>
    <description>E. Nasonov, M. Ivanova, M. Samsonov, T. Tyabut, M. C. Genovese; 2020 THU0176 Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results CREDO-1 study</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>October 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2020</results_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>moderate Rheumatoid Arthritis</keyword>
  <keyword>severe Rheumatoid Arthritis</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>Olokizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02760368/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was conducted at 42 clinical sites (in Belarus, Bulgaria, Russia,Turkey) between May 2016 and April 2018. 785 patients were included, 357 patients screen- failured, 428 patients were randomized (143 patients in OKZ q2w +MTX group, 142 patients in OKZ q4w +MTX group, 143 patients in Placebo q2w +MTX group). 427 patients were treated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 2: Olokizumab q2w</title>
          <description>Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="P2">
          <title>Arm 1: Olokizumab q4w</title>
          <description>Olokizumab 64 mg Subcutaneous q4w +placebo+ Methotrexate (oral)&#xD;
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="P3">
          <title>Arm 3: Placebo</title>
          <description>Placebo Subcutaneous q2w + Methotrexate (oral)&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Olokizumab q4w + Methotrexate</title>
          <description>Olokizumab 64 mg Subcutaneous q4w +placebo q4w+ Methotrexate (oral)&#xD;
Olokizumab q4w: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial + placebo (sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules)</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Olokizumab q2w + Methotrexate</title>
          <description>Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)&#xD;
Olokizumab q2w: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial</description>
        </group>
        <group group_id="B3">
          <title>Arm 3: Placebo q2w + Methotrexate</title>
          <description>Placebo Subcutaneous q2w + Methotrexate (oral)&#xD;
Placebo q2w: sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="142"/>
            <count group_id="B2" value="143"/>
            <count group_id="B3" value="143"/>
            <count group_id="B4" value="428"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="378"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.1" spread="12.07"/>
                    <measurement group_id="B2" value="52.0" spread="11.77"/>
                    <measurement group_id="B3" value="52.7" spread="11.29"/>
                    <measurement group_id="B4" value="51.3" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="354"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>participants</title>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="427"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other/Mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belarus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.401" lower_limit="14.88" upper_limit="46.23"/>
                    <measurement group_id="B2" value="26.621" lower_limit="16.98" upper_limit="45.52"/>
                    <measurement group_id="B3" value="26.929" lower_limit="17.46" upper_limit="51.56"/>
                    <measurement group_id="B4" value="26.650" lower_limit="14.88" upper_limit="51.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Disease Severity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Inactive (DAS28 (CRP) ≤ 3.2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately Active (DAS28 (CRP) &gt; 3.2 to ≤ 5.1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Active (DAS28 (CRP) &gt; 5.1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response</title>
        <description>The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. (a responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12)</description>
        <time_frame>at Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64 mg Subcutaneous q4w + Placebo + Methotrexate (oral)&#xD;
Olokizumab 64 mg Subcutaneous once every 4 weeks+placebo in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+ concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or ≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Placebo q2w + Methotrexate</title>
            <description>Placebo Subcutaneous q2w + Methotrexate (oral)&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response</title>
          <description>The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. (a responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12)</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The OKZ ACR20 response rates for 64 q2w treatment group at Week 12 are expected to be at least 55%, resulting in an expected difference in ACR20 response rates of 30 percentage points between respective OKZ treatment group and placebo. Sample size yield 100% disjunctive power for testing the primary hypothesis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.378</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.248</ci_lower_limit>
            <ci_upper_limit>0.489</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The OKZ ACR20 response rates for 64 q4w treatment group at Week 12 are expected to be at least 50%, resulting in an expected difference in ACR20 response rates of 25 percentage points between respective OKZ treatment group and placebo. Sample size yield 100% disjunctive power for testing the primary hypothesis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.445</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.318</ci_lower_limit>
            <ci_upper_limit>0.552</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between OKZ and Placebo in the Percentage of Subjects Achieving Low Disease Activity</title>
        <description>Defined as DAS28 (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12.</description>
        <time_frame>at Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64 mg Subcutaneous q4w + Placebo + Methotrexate (oral)&#xD;
Olokizumab 64 mg Subcutaneous once every 4 weeks+placebo in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+ concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or ≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Placebo q2w + Methotrexate</title>
            <description>Placebo Subcutaneous q2w + Methotrexate (oral)&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between OKZ and Placebo in the Percentage of Subjects Achieving Low Disease Activity</title>
          <description>Defined as DAS28 (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12.</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>DAS28 low disease activity (based on DAS28 [CRP] &lt;3.2) response rate at Week 12 was estimated to be 10% in the placebo group and 30% in 64 q2w OKZ treatment groups respectively, resulting in an expected difference of 20 percentage points between OKZ q2w treatment group and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.301</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.203</ci_lower_limit>
            <ci_upper_limit>0.396</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>DAS28 low disease activity (based on DAS28 [CRP] &lt;3.2) response rate at Week 12 was estimated to be 10% in the placebo group and 22% in 64 mg q4w OKZ treatment group respectively, resulting in an expected difference of 12 percentage points between OKZ q4w treatment group and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.352</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.251</ci_lower_limit>
            <ci_upper_limit>0.449</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between OKZ and Placebo in the Improvement of Physical Ability</title>
        <description>As measured by the Health Assessment Questionnaire Disability Index (HAQ DI) HAQ-DI provides an assessment of the impact of the disease and its treatment on physical function. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64 mg Subcutaneous q4w + Placebo + Methotrexate (oral)&#xD;
Olokizumab 64 mg Subcutaneous once every 4 weeks+placebo in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+ concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or ≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Placebo q2w + Methotrexate</title>
            <description>Placebo Subcutaneous q2w + Methotrexate (oral)&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between OKZ and Placebo in the Improvement of Physical Ability</title>
          <description>As measured by the Health Assessment Questionnaire Disability Index (HAQ DI) HAQ-DI provides an assessment of the impact of the disease and its treatment on physical function. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category).</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.471"/>
                    <measurement group_id="O2" value="1.64" spread="0.499"/>
                    <measurement group_id="O3" value="1.78" spread="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (visit 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.540"/>
                    <measurement group_id="O2" value="1.07" spread="0.512"/>
                    <measurement group_id="O3" value="1.54" spread="0.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline (obseved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.493"/>
                    <measurement group_id="O2" value="-0.53" spread="0.542"/>
                    <measurement group_id="O3" value="-0.22" spread="0.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.059</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.059</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR50 Response</title>
        <description>Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 24.</description>
        <time_frame>at Week 24</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64 mg Subcutaneous q4w + Placebo + Methotrexate (oral)&#xD;
Olokizumab 64 mg Subcutaneous once every 4 weeks+placebo in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+ concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or ≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Placebo q2w + Methotrexate</title>
            <description>Placebo Subcutaneous q2w + Methotrexate (oral)&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response</title>
          <description>Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 24.</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.350</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.239</ci_lower_limit>
            <ci_upper_limit>0.450</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.409</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.296</ci_lower_limit>
            <ci_upper_limit>0.509</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤2.8 (Remission)</title>
        <description>Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 24</description>
        <time_frame>at Week 24</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64 mg Subcutaneous q4w + Placebo + Methotrexate (oral)&#xD;
Olokizumab 64 mg Subcutaneous once every 4 weeks+placebo in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+ concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or ≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Placebo q2w + Methotrexate</title>
            <description>Placebo Subcutaneous q2w + Methotrexate (oral)&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤2.8 (Remission)</title>
          <description>Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 24</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.025</p_value>
            <p_value_desc>2x2 chi-square test.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.084</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.032</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.025</p_value>
            <p_value_desc>2x2 chi-square test</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.077</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AE) were collected from the signature of the informed consent form until the last visit of the subject in the study (up to 22 weeks after the final dose of study treatment) regardless of relationship to study treatment. Any SAE with a start date after the Safety Follow-Up Period was not required to be reported unless the Investigator thought that the event might be related to either the study treatment, study treatment administration, or a protocol procedure.</time_frame>
      <desc>All AEs and SAEs reported below are related to the Safety Population (safety population included all subjects who receive at least 1 dose of study treatment).&#xD;
Data for TEAEs were reported below. A Treatment Emergent Adverse Event (TEAE) is defined as an AE that first occurred or worsened in severity after the first dose of the study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 2: Olokizumab q2w + Methotrexate</title>
          <description>Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="E2">
          <title>Arm 1: Olokizumab q4w + Methotrexate</title>
          <description>Olokizumab 64 mg Subcutaneous q4w + Placebo + Methotrexate (oral)&#xD;
Olokizumab 64 mg Subcutaneous once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.) + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or ≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: Placebo q2w + Methotrexate</title>
          <description>Placebo Subcutaneous q2w + Methotrexate (oral)&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose of 15 to 25 mg/week (or&#xD;
≥10 mg/week if there is documented intolerance to higher doses) with a stable route of administration (oral, Subcutaneous, or intramuscular)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="143"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="142"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Monocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Aortic valve calcification</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Premature menarche</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dental cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Adrenal atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to plants</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="143"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="142"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="143"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="142"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="143"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="143"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Mycobacterium tuberculosis complex test positive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>N-terminal prohormone brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Adiponectin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood homocysteine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Haematocrit increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Interferon gamma release assay positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Monocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Protein total increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Red blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Periostitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sweat discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Arterial insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any study related information could be made public available only after Sponsors written permission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elena Korneva, Senior Scientific Advisor</name_or_title>
      <organization>R-Pharm</organization>
      <phone>0074959567937 ext 3819</phone>
      <email>korneva@rpharm.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

